[HTML][HTML] Evolution of cancer pharmacological treatments at the turn of the third millennium
The medical history of cancer began millennia ago. Historical findings of patients with
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …
cancer date back to ancient Egyptian and Greek civilizations, where this disease was …
[HTML][HTML] Second-generation antiandrogens: from discovery to standard of care in castration resistant prostate cancer
MA Rice, SV Malhotra, T Stoyanova - Frontiers in oncology, 2019 - frontiersin.org
Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …
[HTML][HTML] Implementing genome-driven oncology
Early successes in identifying and targeting individual oncogenic drivers, together with the
increasing feasibility of sequencing tumor genomes, have brought forth the promise of …
increasing feasibility of sequencing tumor genomes, have brought forth the promise of …
Enhancing global access to cancer medicines
J Cortes, JM Perez‐García… - CA: a cancer journal …, 2020 - Wiley Online Library
Globally, cancer is the second leading cause of death, with numbers greatly exceeding
those for human immunodeficiency virus/acquired immunodeficiency syndrome …
those for human immunodeficiency virus/acquired immunodeficiency syndrome …
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
A detailed understanding of the mechanisms by which tumors acquire resistance to targeted
anticancer agents should speed the development of treatment strategies with lasting clinical …
anticancer agents should speed the development of treatment strategies with lasting clinical …
[HTML][HTML] Anticancer effects of fucoxanthin through cell cycle arrest, apoptosis induction, angiogenesis inhibition, and autophagy modulation
SA Ahmed, P Mendonca, R Elhag… - International Journal of …, 2022 - mdpi.com
Cancer accounts for one in seven deaths worldwide and is the second leading cause of
death in the United States, after heart disease. One of the standard cancer treatments is …
death in the United States, after heart disease. One of the standard cancer treatments is …
Resistance to trastuzumab in breast cancer
PR Pohlmann, IA Mayer, R Mernaugh - Clinical cancer research, 2009 - AACR
HER2 is a transmembrane oncoprotein encoded by the HER2/neu gene and is
overexpressed in approximately 20 to 25% of invasive breast cancers. It can be …
overexpressed in approximately 20 to 25% of invasive breast cancers. It can be …
Natural course and biology of CML
B Chereda, JV Melo - Annals of hematology, 2015 - Springer
Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in the
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …
haemopoietic stem cell (HSC) compartment. This disease is characterised by a reciprocal t …
Mechanisms of resistance to ABL kinase inhibition in chronic myeloid leukemia and the development of next generation ABL kinase inhibitors
AB Patel, T O'Hare… - Hematology/Oncology …, 2017 - hemonc.theclinics.com
Every year, more than 8000 new cases of chronic myeloid leukemia (CML) are diagnosed in
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …
the United States. 1 BCR-ABL1, a fusion protein kinase derived from a reciprocal …
[HTML][HTML] Drug repositioning for personalized medicine
Human diseases can be caused by complex mechanisms involving aberrations in numerous
proteins and pathways. With recent advances in genomics, elucidating the molecular basis …
proteins and pathways. With recent advances in genomics, elucidating the molecular basis …